Switching to a Second TNF-α Inhibitor in a Patient with Severe Juvenile Polyarthritis: A Clinical Case

Background. Insufficient efficacy or intolerance of the first TNF-α inhibitor in patients with juvenile idiopathic arthritis (JIA) is an indication for the appointment of a second inhibitor. Golimumab is a new TNF-α inhibitor registered for treating JIA under pediatric indications. Clinical Case Des...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Ekaterina V. Denisova, Ekaterina I. Alexeeva, Tatyana M. Dvoryakovskaya, Margarita A. Soloshenko, Anna V. Mamutova, Kseniya B. Isayeva, Anna N. Fetisova
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	"Paediatrician" Publishers LLC 2018-10-01
סדרה:	Вопросы современной педиатрии
נושאים:	children juvenile idiopathic arthritis genetically engineered biological preparations golimumab infliximab
גישה מקוונת:	https://vsp.spr-journal.ru/jour/article/view/1931
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!